ClinicalTrials.gg
CompletedNCT00594165SP512OLUpdated Oct 2, 2014Results posted

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.

A Phase 3 interventional study of Rotigotine in Early-Stage Parkinson's Disease, sponsored by UCB Pharma. Completed at 42 sites in 2 countries. Open to participants aged 31 Years and older. Per ClinicalTrials.gov, last updated 2014-10-02.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
217
Allocation
Not applicable
Ages
31 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.

Enrollment
13th of 42
217 · median 123
Started
2002
with 2 others
Phase 3
20 of 44
none open now
Registered
16th of 44
by date
Lead sponsor
22 of 44
UCB Pharma

Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 13th largest by enrollment of the 42 interventional ones that give a count, is one of 3 that started in 2002, is one of 20 in phase 3, and was the 16th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 31 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing rotigotine in Parkinson Disease, or all of them as a file.
02

Study summary

The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with early-stage idiopathic Parkinson's disease.

Read the detailed description

This is the open-label extension to the randomized, double-blind, placebo-controlled SP512 trial that assessed the efficacy and safety and tolerability of the Rotigotine patch in subjects with early-stage idiopathic Parkinson's Disease.

03

Conditions studied

  • Early-Stage Parkinson's Disease

Browse trials for

Keywords

  • Rotigotine
04

Who can participate

Ages eligible
31 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who have completed six months of maintenance treatment in the SP512 double-blind trial

Exclusion criteria

Exclusion Criteria:

  • Subjects who had an ongoing serious adverse event from SP512 double-blind trial that was assessed as related to study medication
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
217 participants (actual)

Study arms

  • Experimental
    Rotigotine

    Rotigotine

    Drug: Rotigotine

Interventions

  • Rotigotine trans-dermal patches: 10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours) Optimal dosing: During the first year: The maximum Rotigotine dose allowed is 6 mg/24 hours. After the first year: allowed dose increase of Rotigotine up to a maximum of 16 mg/24 hours.

    Also known as: Neupro

06

What researchers measure

Primary outcomes

  1. Number of Subjects With at Least One Adverse Event During This Open-label Extension Study

    Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.

    Time frame: 7 years

Secondary outcomes

  1. Number of Subjects Who Withdrew From the Trial Due to an Adverse Event.

    Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.

    Time frame: 7 years

  2. Mean Epworth Sleepiness Scale Score During the Open-label Extension.

    The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions. The total ESS score is the sum of 8 item-scores and can range between 0 and 24. The higher the score, the higher the person's level of daytime sleepiness.

    Time frame: Visit 9 (end of year 1), Visit 13 (end of year 2), Visit 17 (end of year 3), Visit 21(end of year 4), Visit 25 (end of year 5), Visit 29 (end of year 6), End of Treatment (last study visit or early withdrawal visit)

07

Results

Posted Feb 25, 2010

Participant flow

An Open-Label Extension to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects with Early-Stage Idiopathic Parkinson's Disease from June 2002 to November 2008

Participant flow — Overall Study
MilestoneRotigotine
Started217
Completed0
Not completed217
Withdrew: Major protocol violation1
Withdrew: Lack of efficacy12
Withdrew: Adverse event52
Withdrew: Unsatisfactory compliance of subject6
Withdrew: Subject withdrew consent27
Withdrew: Study ended per sponsor102
Withdrew: Lost to follow-up4
Withdrew: Other: pi discretion5
Withdrew: Other: subject moving3
Withdrew: Other: brain surgery controlled symptoms1
Withdrew: Other: house bound; can't get to clinic1
Withdrew: Other: subject enrolled in other trial1
Withdrew: Other: site terminated participation2

Outcome measures

PrimaryNumber of Subjects With at Least One Adverse Event During This Open-label Extension Study

Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.

Time frame:
7 years
Reported as:
Number · Subjects
Number of Subjects With at Least One Adverse Event During This Open-label Extension Study
SubjectsRotigotine
Number of Subjects With at Least One Adverse Event During This Open-label Extension Study214
SecondaryNumber of Subjects Who Withdrew From the Trial Due to an Adverse Event.

Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.

Time frame:
7 years
Reported as:
Number · subjects
Number of Subjects Who Withdrew From the Trial Due to an Adverse Event.
subjectsRotigotine
Number of Subjects Who Withdrew From the Trial Due to an Adverse Event.52
SecondaryMean Epworth Sleepiness Scale Score During the Open-label Extension.

The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions. The total ESS score is the sum of 8 item-scores and can range between 0 and 24. The higher the score, the higher the person's level of daytime sleepiness.

Time frame:
Visit 9 (end of year 1), Visit 13 (end of year 2), Visit 17 (end of year 3), Visit 21(end of year 4), Visit 25 (end of year 5), Visit 29 (end of year 6), End of Treatment (last study visit or early withdrawal visit)
Reported as:
Mean · Score on a scale
Mean Epworth Sleepiness Scale Score During the Open-label Extension.
Score on a scaleRotigotine
Visit 9 (end of year 1) (n=209)7.3 ± 4.4
Visit 13 (end of year 2) (n=209)7.9 ± 4.9
Visit 17 (end of year 3) (n=209)8.2 ± 5.2
Visit 21 (end of year 4) (n=209)8.4 ± 5.0
Visit 25 (end of year 5) (n=209)8.8 ± 5.0
Visit 29 (end of year 6) (n=209)8.5 ± 5.0
End of Treatment (n=216)9.0 ± 5.4

Adverse events

Collected over Up to 7 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rotigotine—102/216 (47.2%)206/216 (95.4%)
Most frequent serious events
Showing 10 of 132
Most frequent serious events
EventRotigotine
Myocardial infarctionCardiac disorders6/216
Chest painGeneral disorders6/216
PneumoniaInfections and infestations5/216
Hip fractureInjury, poisoning and procedural complications5/216
OsteoarthritisMusculoskeletal and connective tissue disorders5/216
Parkinson's diseaseNervous system disorders5/216
Spinal column stenosisMusculoskeletal and connective tissue disorders4/216
SyncopeNervous system disorders4/216
Pulmonary embolismRespiratory, thoracic and mediastinal disorders4/216
Coronary artery diseaseCardiac disorders3/216
Most frequent other events
Showing 10 of 61
Most frequent other events
EventRotigotine
SomnolenceNervous system disorders116/216
Oedema peripheralGeneral disorders79/216
FallInjury, poisoning and procedural complications69/216
NauseaGastrointestinal disorders66/216
DizzinessNervous system disorders58/216
Back painMusculoskeletal and connective tissue disorders53/216
ArthralgiaMusculoskeletal and connective tissue disorders51/216
InsomniaPsychiatric disorders47/216
Pain in extremityMusculoskeletal and connective tissue disorders40/216
DepressionPsychiatric disorders38/216

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Rotigotine
<=18 years0
Between 18 and 65 years119
>=65 years97
Age, Continuous
Age, Continuous(years)Rotigotine
Mean63.2 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)Rotigotine
Female69
Male147
Region of Enrollment
Region of Enrollment(participants)Rotigotine
United States186
Canada30
08

Study locations

42 sites
  • Peoria, Arizona, United States
  • Phoenix, Arizona, United States
  • Tucson, Arizona, United States
  • Fountain Valley, California, United States
  • Fresno, California, United States
  • Los Angeles, California, United States
  • Englewood, Colorado, United States
  • Danbury, Connecticut, United States
  • New Haven, Connecticut, United States
  • Miami, Florida, United States
  • Pompano Beach, Florida, United States
  • Sunrise, Florida, United States
  • Atlanta, Georgia, United States
  • Chicago, Illinois, United States
  • Fort Wayne, Indiana, United States
  • New Orleans, Louisiana, United States
  • Boston, Massachusetts, United States
  • Southfield, Michigan, United States
  • Minneapolis, Minnesota, United States
  • St. Louis, Missouri, United States
  • Henderson, Nevada, United States
  • New Brunswick, New Jersey, United States
  • Albany, New York, United States
  • Louisville, New York, United States
  • New York, New York, United States
  • Asheville, North Carolina, United States
  • Durham, North Carolina, United States
  • Cleveland, Ohio, United States
  • Columbus, Ohio, United States
  • Toledo, Ohio, United States
  • Upland, Pennsylvania, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Richmond, Virginia, United States
  • Roanoke, Virginia, United States
  • Milwaukee, Wisconsin, United States
  • Calgary, Alberta, Canada
  • Edmonton, Alberta, Canada
  • Vernon, British Columbia, Canada
  • Ottawa, Ontario, Canada
  • Saskatoon, Saskatchewan, Canada
09

References and documents

Publications

  • Elmer LW, Surmann E, Boroojerdi B, Jankovic J. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study. Parkinsonism Relat Disord. 2012 Jun;18(5):488-93. doi: 10.1016/j.parkreldis.2012.01.008. Epub 2012 Feb 10. PubMed 22326237 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2002, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2010, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2007
First posted
Jan 15, 2008
Start
Jun 2002
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Results first posted
Feb 25, 2010
Last update
Oct 2, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00594165
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Jan 15, 2008
Start date
Jun 2002
Primary completion
Nov 2008
Completion
Nov 2008
Results posted
Feb 25, 2010
Last update
Oct 2, 2014

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion